Find A Clinical Trial
Disease Type: Solid Tumors All
A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor, TOS-358, in Adult Subjects with Select Solid Tumors
Principal Investigator
Alexander I. Spira, MD, PhD, FACPNP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
Principal Investigator
Alexander I. Spira, MD, PhD, FACP“Phase 1, first-in-human, open-label dose escalation and cohort expansion study of KB-0742 in patients with relapsed or refractory solid tumors or non-Hodgkin lymphoma”
Principal Investigator
Alexander I. Spira, MD, PhD, FACP“A PHASE Ia/Ib, OPEN-LABEL, MULTICENTER, GLOBAL, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF XmAb24306 AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS”
Principal Investigator
Alexander I. Spira, MD, PhD, FACPPhase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients with Advanced Malignancies Associated with EphA2 Expression
Principal Investigator
Alexander I. Spira, MD, PhD, FACPA Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the anti-PD-1 Monoclonal Antibody BGB-A317 in combination with the PARP inhibitor BGB-290 in Subjects with Advanced Solid Tumors
Principal Investigator
Alexander I. Spira, MD, PhD, FACP“A PHASE 1/1B STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF AB308 IN COMBINATION WITH AB122 IN PARTICIPANTS WITH ADVANCED MALIGNANCIES”
Principal Investigator
Alexander I. Spira, MD, PhD, FACP“A PHASE I, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND COHORT EXPANSION STUDY OF SPYK04 AS MONOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS (SPK101JG)”
Principal Investigator
Alexander I. Spira, MD, PhD, FACP“A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients with Advanced Solid Malignancies and Lymphoma with an Expansion in Select Malignancies (RGX-104-001)”
Principal Investigator
Alexander I. Spira, MD, PhD, FACP“20190135: A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib (AMG 510) in Combination with TNO155 in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreaK 101 Subprotocol N) “
